Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Klarity Drops is a compounded, preservative-free ophthalmic solution developed by ImprimisRx (a division of Harrow Health). The formulation features glycerin as the primary active ingredient, delivered in a proprietary chondroitin sulfate vehicle. It is designed to provide ocular lubrication and relief from symptoms associated with dry eye disease and keratoconjunctivitis sicca. As a compounded medication, it is typically produced in 503(b) outsourcing facilities to provide a high-quality, sterile, and preservative-free alternative for patients who may be sensitive to standard ophthalmic preservatives. Klarity Drops is part of a product line that also includes Klarity-C, which contains cyclosporine; however, the standard Klarity Drops formulation focuses on lubricant-based relief through its humectant and protective properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Klarity Drops.